China Pharma Holdings

China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. The firm’s product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HAIKOU CITY, China , March 26, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the fiscal year ended December 31, 20 20 . Full Year Highlights Revenue was both $10.9 million in fiscal year 2020 and 2019 , respectively ; Gross margin was 1 8.0 % in fiscal year 20 20 , compared to 1 3.6 % in fiscal year 201 9; Loss from operations was $2 .6 million in fiscal year 20 20 compared to $ 2 0.4 million in fiscal year 201 9 , which represented a n improvement of $ 17.8 million; Net loss was $2 .9 million in fiscal year 20 20 compared to $ 20.7 million in fiscal year 201 9.

China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results

Face mask play China Pharma Holdings is trending higher today, and investors are noticing. Here is what you should know about CPHI stock.

China Pharma Holdings: 5 Things for Potential CPHI Stock Investors to Know

China Pharma Holdings Inc. (CPHI) CEO Zhilin Li on Q4 2019 Results - Earnings Call Transcript

China Pharma's (CPHI) CEO Zhilin Li on Q2 2019 Results - Earnings Call Transcript

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q1 2019 Results - Earnings Call Transcript

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q4 2018 Results - Earnings Call Transcript

News for China Pharma Holdings Stock (CPHI)